They bought the shares. Sunrun shares. A simple transaction. A little bit of hope, a little bit of speculation, all wrapped up in publicly traded stock. The value, as of the end of the quarter, was nine point two million. The market, as always, does what it wants. So it goes.
The figures, as presented, are perfectly respectable, though one does wonder if Mr. Gary is planning a particularly lavish holiday. The transaction value, based on the SEC Form 4’s reported price of $55.47, seems perfectly reasonable, and the post-transaction calculations, while a bit of a bother for a simple investor like myself, appear to be in order.
So, two things are likely to define Alibaba’s next act. And I’m not talking a dramatic monologue; I’m talking actual business developments. Buckle up.
The reduction leaves DAFNA holding 476,826 shares, still representing $15.61 million at the period’s close. The fund’s continued investment, despite the trimming, suggests not outright disapproval, but a recalibration. One must ask: what prompts such a move after a period of considerable appreciation? The answer, predictably, is not a simple one.
Note the indirect nature of the acquisition. The shares are held via The Wesley and Katherine Mitchell Living Trust – a perfectly respectable arrangement, of course, but one that adds a layer of delightful opacity. It’s always more interesting when things aren’t entirely straightforward. The price, a mere $42.48 per share, suggests either remarkable foresight or a certain…optimism.
The pronouncements surrounding AI are legion, the capital expenditure astronomical. One anticipates, therefore, a corresponding ascent in valuation. Instead, a muted performance, a quiet retreat. This discrepancy, observed by many, has prompted speculation of a bubble’s deflation. However, I propose a different interpretation, one informed by the apocryphal writings of the cartographer, Señor Valerius. He posited that true value is not found in the readily apparent, but in the distortions, the anomalies that betray a deeper, hidden order.
The filing reveals a subtle shift in DAFNA’s holdings. The stake, once a more prominent bloom within the portfolio, now represents 1.36% of the fund’s $430.52 million in reportable assets, a gentle decline from the previous quarter’s 1.90%. It is as if the fund, observing the stock’s ascent, has simply rebalanced its bouquet, ensuring no single flower overshadows the others.
They increased their holdings in Biohaven during the last quarter of 2025. Another $8.92 million. The total stake? $10.78 million. Up from before. More shares. A slightly bigger number on a spreadsheet. The stock, of course, has other ideas. It’s down, dramatically, and that’s the thing, isn’t it? We chase numbers while the world does what it will.
The figures, presented thusly, offer a cold precision, yet conceal the warmth of human ambition and the chill of market uncertainty. The value assigned, derived from the weighted average purchase price of $58.98, and the closing price of $52.88 on the eighteenth of March, are but fleeting measurements, susceptible to the whims of fortune and the anxieties of investors.
The filing with the Securities and Exchange Commission reveals a new stake, a deliberate entry into a company that has, of late, failed to impress. Apellis currently represents 1.93% of RTW Investment’s reportable assets as of December 31, 2025 – a not insignificant sum, but hardly a commitment that would signal a complete shift in strategy.